Anti-CD20 (Ofatumumab), Human IgG1 Antibody

Anti-CD20 (Ofatumumab), Human IgG1 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a human IgG1 kappa monoclonal antibody that acts as a CD20 antagonist. CD20 is usually expressed on pre- and mature B lymphocytes, as well as malignant B lymphocytes. The Fab domain of the antibody binds to the large and small extracellular loops of the CD20 molecule but does not cause immediate shedding and internalization of CD20. Instead, the binding persists on B cell surface for an extended time, which helps recruit innate effectors such as macrophages that induce complement-dependent and antibody-dependent cellular cytotoxicity and cause B cell lysis. The original drug was approved by the FDA to treat progressive or recurrent chronic lymphocytic leukemia (CLL), or in CLL patients who were refractory to fludarabine-based therapy

Immunogen Sequence:Human CD20

Target Alternative Name:HuMax-CD20, 2F2, B1, S7, Bp35, CVID5, MS4A2, LEU-16, MS4A1

Species Reactivities:Human

Tag Line:The biosimilar is a human monoclonal antibody that targets CD20 and induces cytotoxicity in B cells via complement-dependent and antibody-dependent cellular cytotoxicity

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.